Reuters logo
8 months ago
BRIEF-Transgene says UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo
December 7, 2016 / 4:55 PM / 8 months ago

BRIEF-Transgene says UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo

Dec 7 (Reuters) - Transgene:

* Transgene: UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo (Nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (NSCLC)

* Trial is supported by Bristol-Myers Squibb through supply of nivolumab for use in clinical study Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below